Table 1.
Clinicopathological characteristics.
Characteristics | n | |
---|---|---|
Median age at diagnosis of metastasis (range) | 54 (24–89) | |
Menopausal status | Premenopausal | 68 (38.6%) |
Postmenopausal | 97 (55.1%) | |
Unknown | 10 (5.7%) | |
Male | 1 (0.6%) | |
Type of metastasis | De novo metastasis | 27 (15.3%) |
Relapsed | 146 (83.0%) | |
Unknown | 3 (1.7%) | |
Total number of metastatic sites | < 3 | 76 (43.2%) |
≥ 3 | 90 (51.1%) | |
Unknown | 10 (5.7%) | |
Site of metastatic biopsy | Locoregional | 50 (27.2%) |
Distant | 134 (72.8%) | |
Metastatic spread | Bone‐only | 15 (8.5%) |
Visceral | 145 (82.4%) | |
Organ of biopsy | Bone | 33 (17.9%) |
Brain | 22 (12.0%) | |
Breast | 24 (13.0%) | |
Liver | 31 (16.9%) | |
Lung | 13 (7.1%) | |
Lymph node | 16 (8.7%) | |
Muscle | 2 (1.1%) | |
Ovary | 4 (2.2%) | |
Peritoneum | 2 (1.1%) | |
Pleura | 10 (5.4%) | |
Skin | 27 (14.7%) | |
IHC group of the metastatic biopsy | HR+/HER2‐ | 100 (54.4%) |
HER2+ | 18 (9.8%) | |
TNBC | 53 (28.8%) | |
Unknown | 13 (7.1%) | |
PAM50 molecular subtype of the metastatic biopsy | Luminal A | 30 (16.3%) |
Luminal B | 47 (25.5%) | |
HER2‐enriched | 42 (22.8%) | |
Basal‐like | 54 (29.4%) | |
Normal‐like | 11 (6.0%) | |
Previous (neo)adjuvant treatment | 129 (73.3%) | |
Median number of lines of treatment for metastatic disease (range) | 3 (0–13) | |
Treatments received in the metastatic setting | Endocrine therapy | 111 (63.1%) |
CDK4/6 inhibitors | 84 (47.7%) | |
Anti‐HER2 therapies | 28 (15.9%) | |
Chemotherapy | 125 (71.0%) | |
Immunotherapy | 10 (5.7%) | |
Everolimus | 22 (12.5%) | |
PI3K inhibitors | 18 (10.2%) | |
AKT inhibitors | 2 (1.1%) | |
Bevacizumab | 15 (8.5%) | |
PARP inhibitors | 3 (1.7%) | |
Radiotherapy | 111 (63.1%) |